The startup develops long-acting human monoclonal antibodies for the prophylaxis and treatment of infectious diseases in immunocompromised patients who cannot generate adequate antibody responses post-vaccination. By providing a convenient intramuscular administration, the company ensures accessible treatment options that enhance the health and well-being of vulnerable populations.
Funding
$12.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Immunocompromised patients, such as transplant recipients, often exhibit inadequate responses to traditional vaccines due to immunosuppressive therapies required to prevent organ rejection. This leaves them highly vulnerable to severe viral infections, including SARS-CoV-2 and BK Virus (BKV), leading to complications and poor transplant outcomes.
Solution
SpikImm develops long-acting human monoclonal antibodies (mAbs) designed to provide immediate and sustained protection against severe viral infections in immunocompromised patients. These mAbs offer a prophylactic approach for patients who cannot generate sufficient antibody responses post-vaccination. By targeting viruses such as SARS-CoV-2 and BKV, SpikImm's portfolio aims to reduce the risk of severe complications, improve transplant outcomes, and enhance the overall quality of life for vulnerable patient populations. The mAbs are administered intramuscularly, ensuring convenient and accessible treatment options.
Target Audience
The primary target audience includes transplant patients (kidney and hematopoietic stem cell transplant recipients) and other immunocompromised individuals at high risk of developing severe viral infections.
Features
- Portfolio of long-acting human monoclonal antibodies (mAbs) targeting various viruses
- Prophylactic mAbs designed for immunocompromised patients with inadequate vaccine responses
- Specifically targets viruses such as SARS-CoV-2 and BK Virus (BKV)
- Intramuscular administration for convenient and accessible treatment
- Designed to provide broad, immediate, and long-lasting protection